ESMO 2024 Highlights: Presenter Vignette – Fred Saad

Dr. Fred Saad

Fred Saad

CQ MD FRCS FCAHS

Centre Hospitalier de l’Université de Montréal

Abstract# LBA68

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARANOTE trial